Axsome Therapeutics (AXSM) Current Assets (2015 - 2026)

Axsome Therapeutics has reported Current Assets for 12 years, with the latest figure at $611.2 million in Q1 2026.

• Quarterly Current Assets rose 23.57% year-over-year to $611.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $611.2 million (up 23.57% YoY) and the FY2025 annual result came in at $589.0 million, up 21.42% from the prior year.
• Current Assets improved to $611.2 million in Q1 2026 per AXSM's latest filing, from $589.0 million in the prior quarter.
• Over five years, Current Assets peaked at $611.2 million in Q1 2026 and troughed at $86.8 million in Q1 2022.
• A 5-year average of $424.3 million and a median of $485.1 million in 2024 frame the typical range for Current Assets.
• The sharpest annual moves came in 2022 and 2023: Current Assets sank 47.39% in 2022, then jumped 399.81% in 2023.
• Over 5 years, Current Assets stood at $245.6 million in 2022, then surged by 105.28% to $504.3 million in 2023, then retreated by 3.81% to $485.1 million in 2024, then gained by 21.42% to $589.0 million in 2025, then increased by 3.77% to $611.2 million in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $611.2 million, $589.0 million, and $565.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.